Immunitybio Stock Buy Hold or Sell Recommendation
| IBRX Stock | USD 5.49 0.55 11.13% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Immunitybio is 'Strong Sell'. Macroaxis provides Immunitybio buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IBRX positions. The advice algorithm takes into account all of Immunitybio's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Immunitybio's buy or sell advice are summarized below:
Real Value 4.41 | Target Price 4.5 | Hype Value 5.6 | Market Value 5.49 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Immunitybio given historical horizon and risk tolerance towards Immunitybio. When Macroaxis issues a 'buy' or 'sell' recommendation for Immunitybio, the advice is generated through an automated system that utilizes algorithms and statistical models.
Immunitybio |
Execute Immunitybio Buy or Sell Advice
The Immunitybio recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Immunitybio. Macroaxis does not own or have any residual interests in Immunitybio or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immunitybio's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Immunitybio Trading Alerts and Improvement Suggestions
| Immunitybio is way too risky over 90 days horizon | |
| Immunitybio appears to be risky and price may revert if volatility continues | |
| Immunitybio has high likelihood to experience some financial distress in the next 2 years | |
| The company currently holds 883.68 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immunitybio until it has trouble settling it off, either with new capital or with free cash flow. So, Immunitybio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immunitybio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immunitybio to invest in growth at high rates of return. When we think about Immunitybio's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 622 K. Net Loss for the year was (583.2 M) with profit before overhead, payroll, taxes, and interest of 240 K. | |
| Immunitybio currently holds about 82.94 M in cash with (366.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Immunitybio has a frail financial position based on the latest SEC disclosures | |
| Roughly 80.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ImmunityBio Trading Up 8 percent - MarketBeat |
Immunitybio Returns Distribution Density
The distribution of Immunitybio's historical returns is an attempt to chart the uncertainty of Immunitybio's future price movements. The chart of the probability distribution of Immunitybio daily returns describes the distribution of returns around its average expected value. We use Immunitybio price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immunitybio returns is essential to provide solid investment advice for Immunitybio.
| Mean Return | 0.77 | Value At Risk | -10.38 | Potential Upside | 10.94 | Standard Deviation | 7.56 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immunitybio historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Immunitybio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunitybio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunitybio backward and forwards among themselves. Immunitybio's institutional investor refers to the entity that pools money to purchase Immunitybio's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rafferty Asset Management, Llc | 2023-12-31 | 739.8 K | Allen Holding Inc | 2023-12-31 | 687.6 K | Amvescap Plc. | 2023-12-31 | 641.4 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 599.7 K | Putnam Investments, Llc., A Franklin Templeton Company | 2023-12-31 | 534.2 K | Nuveen Asset Management, Llc | 2023-12-31 | 522.5 K | Bank Of New York Mellon Corp | 2023-12-31 | 482.4 K | Barclays Plc | 2023-12-31 | 479.5 K | Bsc Private Wealth Management, Llc | 2023-12-31 | 443.3 K | Vanguard Group Inc | 2023-12-31 | 13.3 M | Blackrock Inc | 2023-12-31 | 10.7 M |
Immunitybio Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (19.3M) | (40.9M) | 146.2M | (76.3M) | 160.8M | 168.9M | |
| Free Cash Flow | (156.4M) | (173.4M) | (308.0M) | (436.9M) | (397.3M) | (377.5M) | |
| Depreciation | 14.0M | 12.7M | 14.2M | 18.3M | 18.5M | 9.8M | |
| Other Non Cash Items | 6.2M | 24.1M | 23.1M | 29.4M | 138.3M | 145.2M | |
| Capital Expenditures | 4.3M | 1.7M | 33.6M | 99.4M | 30.6M | 22.7M | |
| Net Income | (160.2M) | (224.2M) | (349.8M) | (417.3M) | (583.2M) | (554.0M) | |
| End Period Cash Flow | 76.0M | 35.1M | 181.3M | 105.0M | 265.5M | 278.7M | |
| Investments | (499K) | (193K) | (71.8M) | 126.7M | (51.6M) | (49.0M) | |
| Net Borrowings | 47.7M | 63.7M | 338.5M | 174.1M | 200.2M | 145.1M | |
| Change To Netincome | (672K) | 12.7M | 58.3M | 29.0M | 33.4M | 25.1M |
Immunitybio Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immunitybio or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immunitybio's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immunitybio stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.39 | |
β | Beta against NYSE Composite | 4.69 | |
σ | Overall volatility | 7.80 | |
Ir | Information ratio | 0.09 |
Immunitybio Volatility Alert
Immunitybio is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunitybio's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunitybio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Immunitybio Fundamentals Vs Peers
Comparing Immunitybio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immunitybio's direct or indirect competition across all of the common fundamentals between Immunitybio and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immunitybio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immunitybio's fundamental indicators could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Immunitybio to competition |
| Fundamentals | Immunitybio | Peer Average |
| Return On Asset | -0.52 | -0.14 |
| Operating Margin | (607.93) % | (5.51) % |
| Current Valuation | 3.95 B | 16.62 B |
| Shares Outstanding | 677 M | 571.82 M |
| Shares Owned By Insiders | 79.61 % | 10.09 % |
| Shares Owned By Institutions | 8.80 % | 39.21 % |
| Number Of Shares Shorted | 54.77 M | 4.71 M |
| Price To Sales | 5,562 X | 11.42 X |
| Revenue | 622 K | 9.43 B |
| Gross Profit | 240 K | 27.38 B |
| EBITDA | (342.85 M) | 3.9 B |
| Net Income | (583.2 M) | 570.98 M |
| Cash And Equivalents | 82.94 M | 2.7 B |
| Cash Per Share | 0.21 X | 5.01 X |
| Total Debt | 883.68 M | 5.32 B |
| Current Ratio | 0.31 X | 2.16 X |
| Book Value Per Share | (0.88) X | 1.93 K |
| Cash Flow From Operations | (366.76 M) | 971.22 M |
| Short Ratio | 12.86 X | 4.00 X |
| Earnings Per Share | (1.15) X | 3.12 X |
| Price To Earnings To Growth | 3.69 X | 4.89 X |
| Target Price | 5.0 | |
| Number Of Employees | 628 | 18.84 K |
| Beta | 0.039 | -0.15 |
| Market Capitalization | 3.34 B | 19.03 B |
| Total Asset | 504.45 M | 29.47 B |
| Retained Earnings | (2.96 B) | 9.33 B |
| Working Capital | 235.8 M | 1.48 B |
| Net Asset | 504.45 M |
Note: Acquisition or disposition of Immunitybio securities by Soonshiong Patrick [view details]
Immunitybio Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Immunitybio . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Immunitybio Buy or Sell Advice
When is the right time to buy or sell Immunitybio? Buying financial instruments such as Immunitybio Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 645.7M | 723.8M | 883.7M | 927.9M | Total Assets | 468.9M | 362.4M | 504.5M | 288.0M |
Use Investing Ideas to Build Portfolios
In addition to having Immunitybio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run USD Crypto Fund Thematic Idea Now
USD Crypto Fund
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Immunitybio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Immunitybio Stock analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Immunitybio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Revenue Per Share 0.001 | Quarterly Revenue Growth 0.904 | Return On Assets (0.52) |
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.